This choice was based on: (i) their differential expression; (ii) their inclusion in hypermethylated CpG islands in neuroblastoma or other neoplasias; (iii) known overexpression after treatment with demethylating agents in various types of cancers; (iv) known downregulation in neuroblastoma; (v) functional relationship with MYCN. The gene discussed is MYCN; the disease is cancer.